The estimated Net Worth of Mark W Hahn is at least $458 Миллион dollars as of 12 August 2024. Mr Hahn owns over 400,000 units of Verona Pharma Plc stock worth over $450,431,593 and over the last 8 years he sold VRNA stock worth over $7,147,763. In addition, he makes $560,068 as Chief Financial Officer at Verona Pharma Plc.
Mr has made over 18 trades of the Verona Pharma Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 400,000 units of VRNA stock worth $1,280,000 on 12 August 2024.
The largest trade he's ever made was selling 600,000 units of Verona Pharma Plc stock on 20 December 2022 worth over $1,272,000. On average, Mr trades about 94,884 units every 64 days since 2017. As of 12 August 2024 he still owns at least 14,939,688 units of Verona Pharma Plc stock.
You can see the complete history of Mr Hahn stock trades at the bottom of the page.
Mark W. Hahn is the Chief Financial Officer at Verona Pharma Plc.
As the Chief Financial Officer of Verona Pharma Plc, the total compensation of Mr Hahn at Verona Pharma Plc is $560,068. There are 2 executives at Verona Pharma Plc getting paid more, with Dr. Kathleen A. Rickard having the highest compensation of $722,762.
Mr Hahn is 58, he's been the Chief Financial Officer of Verona Pharma Plc since . There are 3 older and 3 younger executives at Verona Pharma Plc. The oldest executive at Verona Pharma Plc is Dr. Kathleen A. Rickard, 63, who is the Chief Medical Officer.
Mark's mailing address filed with the SEC is 3 MORE LONDON, RIVERSIDE, LONDON, X0, SE1 2RE.
Over the last 4 years, insiders at Verona Pharma Plc have traded over $308,854,297 worth of Verona Pharma Plc stock and bought 5,029,736 units worth $6,770,194 . The most active insiders traders include Andrew Sinclair, Advisors Llc Orbi Med Capit... и Rishi Gupta. On average, Verona Pharma Plc executives and independent directors trade stock every 18 days with the average trade being worth of $11,234,071. The most recent stock trade was executed by David Zaccardelli on 12 August 2024, trading 400,000 units of VRNA stock currently worth $1,280,000.
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
Verona Pharma Plc executives and other stock owners filed with the SEC include: